In COVID-19 clinical update #120, Dr. Griffin discusses outcomes of SARS-CoV-2 reinfection, CDC recommendation for vaccines in young children, neurodevelopment outcomes in infants of mothers testing positive for COVID during pregnancy, efficacy of monoclonal antibodies and antivirals in hamsters, rebound phenomenon after PAXLOVID in high-risk persons, hospitalization for infection after PAXLOVID treatment, and risk of long COVID with different variants.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• Reinfection outcomes (Research Square)
• CDC recommends vaccine for young children (CDC)
• Neurodevelopment outcomes in infants post-infection (JAMA)
• Efficacy of monoclonal antibodies/antivirals in hamsters (Nature)
• PAXLOVID patient eligibility screening checklist (FDA)
• Remdesivir fact sheet for providers (Veklury) 
• Bebtelovimab fact sheet for providers (FDA)
• PAXLOVID drug interaction checker 
• Rebound phenomenon after PAXLOVID in high-risk persons (IDSA)
• Hospitalization for infection after PAXLOVID treatment (CDC)
• Risk of post acute infection with different variants (the Lancet)
• Contribute to FIMRC fundraiser at PWB
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 912
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]

TWiV provides an update on hepatitis of unknown etiology in children, an experimental nanoparticle vaccine for Epstein-Barr virus, and minimal impact of bamlanivimab therapy on antiviral antibodies induced by vaccination.

Hosts: Vincent Racaniello, Rich Condit, Kathy Spindler, and Brianne Barker

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• Hepatitis of unknown etiology (MMWR)
• Clinical recognition of monkeypox (CDC)
• Epstein-Barr virus nanoparticle vaccine (Cell Rep Med)
• Minimal impact of mAb therapy on COVID vaccine induced antibodies (Sci Trans Med)
• Letters read on TWiV 911
• Timestamps by Jolene. Thanks!

Brianne – A Frog So Small, It Could Not Frog Kathy – A Grand Night In: The Story of Aardman Rich – Archive Vincent – Bandwagoning by Heran Darwin

Intro music is by Ronald Jenkees Send your virology questions and comments to [email protected]

In COVID-19 clinical update #119, Dr. Griffin reviews tixagevimab for infection prevention, ivermectin for outpatient infection treatment, symptom rebound after PAXLOVID treatment, bamlanivimab minimally impacting immune response to vaccination, in-hospital mortality among infection patients, residual viral antigen in patients following infection, usage of Casirvimab/Imdevimab and Remdesivir in infected patients with depleted B-cells, and rheumatic symptoms following infection.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• Tixagevimab-Cilgavimab for infection prevention (NEJM)
• Ivermectin for outpatient infection treatment (medRxiv)
• Symptom rebound after PAXLOVID treatment (IDSA)
• Bamlanivimab minimally impacts immune response to vaccination (Sci Transl Med)
• In-hospital morality among infected patients (IDSA)
• Casirvimab/Imdevimab & Remdesivir for infected B-cell depleted patients (IDSA)
• PAXLOVID patient eligibility screening checklist (FDA)
• Remdesivir fact sheet for providers (Veklury) 
• Bebtelovimab fact sheet for providers (FDA)
• Residual viral antigen in patients post infection (IDSA)
• Rheumatic symptoms following infection (IDSA)
• Contribute to FIMRC fundraiser at PWB
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 910
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]

From ASM Microbe 2022 in Washington DC, Vincent and Michael speak with science artists Michele Banks and Jane Hartman about their work and their inspiration.

Hosts: Vincent Racaniello and Michael Schmidt

Guests: Michele Banks and Jane Hartman

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• Trilobite Glassworks (Jane Hartman)
• Artologica (Michele Banks)
• Science art with Michele Banks (TWiV 352)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your virology questions and comments to [email protected]

TWiV discusses the situation with monkeypox, risk factors for SARS-CoV-2 infections of cats and dogs, and a lineage-tracing mouse model for studying papillomavirus infections.

Hosts: Vincent Racaniello, Rich Condit, and Brianne Barker

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• Monkeypox update (CDC)
• SARS-CoV-2 infection of cats and dogs (Emerg Inf Dis)
• Mouse papillomavirus identification (Vet Patrol)
• Mouse model for papillomavirus infection (eLife)
• Vincent interviews Harald zur Hausen (virology blog)
• Letters read on TWiV 907
• Timestamps by Jolene. Thanks!

Brianne – Microbes Rule! at Liberty Science Center Rich – Artemis I update:  Mission diagram, mission in photos, launch dates Vincent – Eco-sustainable 3D printed house – Tecla

Intro music is by Ronald Jenkees Send your virology questions and comments to [email protected]

In COVID-19 clinical update #118, Dr. Griffin discusses management of hair loss after infection, FDA announcements on vaccine schedule and recommendations, Moderna announcement on bivalent booster candidate, association between vaccination and infection during pregnancy, population-level implications of Israel’s booster campaign, PAXLOVID outcomes during recent infection surge, efficacy and safety of Tixagevimab-cilgavimab, diagnostic accuracy of infection by canines, efficacy of colchicine in hospitalized patients, and factors associated with hospital readmission.  

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• Management of hair loss after infection (NIH)
• FDA announces vaccine schedule meeting (FDA)
• FDA advisory committee recommends NOVAVAX vaccine (Novavax)
• Moderna announces bivalent booster candidate (Moderna)
• Association of vaccination and infection during pregnancy (JAMA)
• Implications of Israeli booster campaign (Science Translational Medicine)
• PAXLOVID patient eligibility screening checklist (FDA)
• Remdesivir fact sheet for providers (Veklury) 
• Bebtelovimab fact sheet for providers (FDA)
• PAXLOVID outcomes during infection surge (Research Square)
• Efficacy and safety of Tixagevimab–cilgavimab (The Lancet)
• Diagnostic accuracy of infection by canines (PLOS ONE)
• Efficacy of colchicine in hospitalized patients (Nature)
• Factors associated with readmission (IDSA) 
• Contribute to FIMRC fundraiser at PWB
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 908
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]

TWiV reviews human monkeypox infections, evidence for human Mimivrus infections, and incidence of long COVID in post-vaccine SARS-CoV-2 infections.

Hosts: Vincent Racaniello, Dickson Despommier, Rich Condit, and Brianne Barker

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• Monkeypox update (ProMedMail)
• Multi-country monkeypox outbreak (WHO)
• Monkeypox new global threat (Science)
• Monkeypox outbreak 9 US states (MMWR)
• Mimivirus in human respiratory samples (Sci Rep)
• Long COVID after post-vaccination infection (Nat Med)
• Letters read on TWiV 906
• Timestamps by Jolene. Thanks!

Dickson – Lake Mead water level very low Brianne – Transplantation of a 3D printed ear made out of human cells Rich – nderstanding Vaccine Safety and the Roles of the FDA and the CDC and The Facts About Vaccine Safety Vincent – My new favorite backpack

Greg – Against the Rules

Intro music is by Ronald Jenkees Send your virology questions and comments to [email protected]

In COVID-19 clinical update #117, Dr. Griffin discusses duration of virus shedding, association between pre-exposure to steroids and infection outcome, post-infection subtypes, rehabilitation for post-acute infection, Tixagevimab/Cilgavimab for infection prevention, antibody prophylaxis and vaccination in kidney transplant recipients, remdesivir and bebtelovimab fact sheets for providers, the updated guidelines on treatment with Famotidine, Paxlovid rebound symptom characterizations, antigen test positivity duration, viral dynamics of variants and isolation, association of inflammation in CS fluid, and transmission dynamics in Ghana.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• Duration of virus shedding (NIH)
• Association between pre-exposure to steroids and infection outcome (CMI)
• Post-infection subtypes (medRxiv)
• Rehabilitation for post-acute infection syndrome (MDPI)
• Tixagevimab/Cilgavimab for infection prevention (medRxiv)
• Antibody prophylaxis & vaccination in kidney transplant recipients (Kidney International)
• Guideline on treatment with Famotidine (IDSA) 
• Remdesivir fact sheet for providers (Veklury) 
• Bebtelovimab fact sheet for providers (FDA)
• PAXLOVID rebound symptom characterization (medRxiv)
• Antigen test positivity duration (medRxiv)
• Viral dynamics of variants and isolation (NIH) 
• Association of inflammation in CS fluid (JAMA)
• Transmission dynamics in Ghana (ASTMH) 
• Contribute to FIMRC fundraiser at PWB
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 905
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]

Vincent travels to Cold Spring Harbor Laboratory to speak with David Baltimore, John Coffin, and Harold Varmus about the discovery in 1970 of retroviral reverse transcriptase and its impact on life sciences research.

Hosts: Vincent Racaniello

Guests: David Baltimore, John Coffin, and Harold Varmus

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• Fifty Years of Reverse Transcriptase (Cold Spring Harbor Laboratory)
• 50th Anniversary of RT discovery (Mol Biol Cell)
• RT in virions of Rous sarcoma virus – Temin (Nature)
• RNA-dependent DNA polymerase in tumor virus particles – Baltimore (Nature)

Intro music is by Ronald Jenkees Send your virology questions and comments to [email protected]

In COVID-19 clinical update #115, Dr. Griffin discusses croup association with infection surge, rhinovirus co-circulation in children, shedding following vaccination, high vaccine efficacy in children 6 mo-5 yr, vaccine protection for hospitalized patients, convalescent plasma as post-exposure prophylaxis, real-world effectiveness of PAXLOVID, effectiveness of PAXLOVID in reducing hospitalization, infection rebound after PAXLOVID, relapse of symptomatic infection after PAXLOVID, remdesivir and bebtelovimab fact sheets for providers, guidelines on usage of anticoagulation drugs, long covid symptoms after vaccination, excess mortality in MA, infection sequelae and immunity, and post infection conditions among adults.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• Croup association with infection surge (PIDS)
• Rhinovirus co-circulation in children (Science Direct)
• Infection shedding following vaccination (MedRxiV)
• High vaccine efficacy in children 6 months to 5 years (Pfizer)
• Protection of vaccine against hospitalized patients (IDSA)
• Convalescent plasma as post-exposure prophylaxis (IDSA)
• Real-world effectiveness of PAXLOVID in Hong-Kong (MedRxiV)
• Effectiveness of PAXLOVID in reducing hospitalization (The Lancet)
• Infection rebound after PAXLOVID (CDC)
• Relapse of symptomatic infection after PAXLOVID (Research Square)
• Remdesivir fact sheet for providers (Veklury) 
• Bebtelovimab fact sheet for providers (FDA)
• Guidelines on usage of anticoagulation drugs (ASH)
• Long covid symptoms after vaccination (BMJ)
• Excess morality in Massachusetts (JAMA)
• Infection sequelae and immunity (Annals of Internal Medicine)
• Post infection conditions among adults (CDC)
• Contribute to FIMRC fundraiser at PWB
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 903
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]